PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
PROCEPT BioRobotics (Nasdaq: PRCT) announced management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, December 2, 2025 at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT) announced management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, December 2, 2025 at 8:30 a.m. ET.
A live webcast and archived recording will be available in the company’s Investors section at https://ir.procept-biorobotics.com, with replays accessible for at least 90 days after the event.
Details
News Market Reaction – PRCT
On Nov 21, the first trading day after this news, PRCT closed 7.06% above the previous close.
Data tracked by StockTitan Argus for the Nov 21 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 37th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Tuesday, December 2 at 8:30 a.m. Eastern Time.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.